Autopsy report · NCT06541405

Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“poor accrual”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 6 months before it stopped.
2 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Early Phase 1
Sponsor: Base Therapeutics (Shanghai) Co., Ltd.
Sponsor type: Industry
Conditions: Relapsed/Refractory Acute Myeloid Leukemia
Interventions: NK520
Participants: 2
Sites: 1
Countries: China

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.